Description of the use of Quetiapine Extended Release (XR) in real-life practice in France
0 Years - 150 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Dec 2015 by AstraZeneca
No locations available
|Main study population|
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients’ age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months.
|Schizophrenia SoC sample|
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
|Bipolar SoC sample|
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].